{"path":".obsidian/plugins/text-extractor/cache/51b6db88b2a5917d2dd1f7a0b8aa0fdf.json","text":"Vet er i n ar y B i o s c i en c e 1: C ar d i o v as c u l ar S y s t em Lec t ur e Ni net een We e k F o u r Sem es t er 2, 2023 Ant i c oagul ant s : pr es c r i pt i ons and poi s ons ! Pr o f e s s o r El i z a b e t h T u d o r et udor @ uni m el b. edu. au VET S 9 0 1 2 4 / VET S 3 0 0 1 4 Th i s l e c t u r e : • Th e m e c h a n i s m o f haem os tas i s (re v i e w ) – Va s o c o n s t r i c t i o n – Pl a t e l e t a c t i v a t i o n – Co a g u l a t i o n ( f i b r i n f o r m a t i o n ) • Dr u g s a n d t o x i c a g e n t s t h a t a f f e c t c o a g u l a t i o n – Or a l a n t i c o a g u l a n t s ( w a r f a r i n ) – Ro d e n t i c i d e s a n d p l a n t b a s e d c o u m a r i n d e r i v a t i v e s – In j e c ta b l e a n ti c o a g u l a n ts ( h e p a r i n ) – Ne w a n t i c o a g u l a n t a g e n t s ( NO A C’ s ) • An t i p l a t e l e t d r u g s – CO X i n h i b i t o r s – AD P r e c e p t o r a n t a g o n i s t s – Gp I I b /IIIa a n ta g o n i s ts • Fi b r i n o l y t i c d r u g s – St r e p t o k i n a s e , a l t e p l a s e So me d e f i n i t i o n s : p h y s i o l o g y • Ha e m o s t a s i s : – Ar r es t of bl ood l os s f r om dam aged v es s el s • Co a g u l a t i o n – Fo r m a t i o n o f a f i b r i n cl o t i n a b l o o d ve sse l • Th r o m b u s – Fo r m s in v iv o • Cl o t – Fo r m s i n st a t i c b l o o d in v it ro Ph y s i o l o g i c a l h a e mo s t a s i s Da m a g e t o b l o o d v e s s e l l e a d s t o : 1. Va s o c o n s t r i c t i o n 2. Pl a t e l e t a d h e s i o n a n d a c t i v a t i o n 3. Fi bri n form ati on TH R O M B U S Ph y s i o l o g i c a l h a e mo s t a s i s 1. Me ch a n i sm o f V a so co n st r i ct i o n Ø Co l l a g e n e x p o s e d o n d a m a g e d v e s s e l wa l l Ø Pl a t e l e t s s t i c k t o c o l l a g e n a n d “ ac ti v ate ” Ø AD P a n d 5 - HT r e l e a s e d f r o m p l a t e l e t s Ø 5 - HT i s a p o we r f u l v a s o c o n s t r i c t o r Ph y s i o l o g i c a l h a e mo s t a s i s 2 M ec hani s m of P l atel et A c ti v ati on and A dhes i on Ø AD P f r om ac t i v at ed pl at el et s c aus es ot her s t o ac t i v at e and c hange sh a p e Ø Gr anul e c ont ent s ar e s ec r et ed ( eg AD P, 5 - HT ) Ø Me d i a t o r s a r e s y n t h e s i s e d ( e g T h r o mb o x a n e ) Ø Pl at el et s aggr egat e and adher e vi a f i b r i n o g e n b r i d g i n g b e t w e e n GPI I b/ I I I a r ec ept or s Ø Sof t pl ug f or m ed Mechani sm of P l at el et A ct i vat i on and Ad h e s i o n Im a g e s P r o fe s s o r S h a u n J a c k s o n h ttp ://w w w .a c b d .m o n a s h .o r g /r e s e a r c h /th r o m b o s i s - re s e a rc h - uni t . ht m l He t e r o g e n e i t y o f p l a t e l e t s h a p e Ac t i v a t e d pl at el et s Ad h e r e n t pl at el et Co p y r i g h t © 2 0 0 6 A m e r i c a n S o c i e t y o f He m a t o l o g y . Co p y r i g h t r e s t r i c t i o n s m a y a p p l y . Jackso n , S . P . et al . B l o o d 2006; 107: 3418 - 3419 Pl a t e l e t Ad h e s i o n Pl a t e l e t A c t i v a t i o n 5 - HT ADP AA TXA 2 Ca ++ COX PLA 2 Ad h e s i o n Ag g r e g a t i o n TXA 2 So me s t i mu l i f o r p l a t e l e t a c t i v a t i o n : Ø Co l l a g e n Ø Th r o m b i n Ø Th r o m b o x a n e Ø AD P Au s t Pr e s c r i b e r ( 3 0 ) p a g e 9 3 2 0 0 7 Ph y s i o l o g i c a l h a e mo s t a s i s 3 M ec hani s m of F i br i n D epos i ti on • Fi b r i n i s f o r m e d f r o m fi br i nogen (a s o l u b l e p l a s m a p ro t e i n ) • Th r o m b i n cl e a ve s f i b r i n o g e n -- > f i b r i n ( i n so l u b l e m o n o m e r s) • Th r o m b i n i s n o t p r e s e n t i n p l a s m a : i t i s p r o d u c e d b y ac ti v ati on of pr othr om bi n Ac t i v a t i o n o f p r o t h r o mb i n • A “ ca sca d e ” reac ti on w here i nac ti v e prec urs ors are ac ti v ated i n s eri es - eac h gi v i ng ri s e to m ore of the nex t • Tw o pathw ay s i n the c as c ade: – Ex t r i n s i c - in v iv o : d a m a g e d t is s u e s r e le a s e thr om bopl as ti n – Intr i ns i c - in v it r o : e x p o s e d c o lla g e n o r o t h e r m a t e r ia l, negati v e c har ges ( eg gl as s ) Co a g u l a t i o n Ca s c a d e Wh a t i s i mp o r t a n t ? ? • A s m a l l s i g n a l ( eg FX I I ) l e a d s t o a l a r g e am ount of pr oduc t ( f i br i n) • Eac h s t ep l eads t o f or m at i on of m or e pr oduc t ie am pl i f i c at i on • Th e ‘ fa c to r s ’ ar e pr ot eas es • Th e e xt r i n si c p a t h w a y i s f a st e r t h a n i n t r i n si c pat hw ay ( t hat has m any m or e s t eps ) Ea c h St e p le a d s t o m o r e pr oduct i e AM PL I FI C A TI O N Co a g u l a t i o n Ca s c a d e : FI BR I N O G EN FI BR I N ST ABL E CL O T TH R O M BI NPR O TH R O M BI N X Xa In tr i n s i c p a th w a y Ex t r i n s i c p a t h w a y Ti s s u e d a m a g e Th r o m b o p l a s t i n VI IVI I a Re l e a s e d f r o m t i s s u e s Ex p o s e d c o l l a g e n + ot her c om pounds XI I XI I a XI XI a IX a IX VI I I V PL D Ca 2+ PL D Ca 2+ Cont r ol of bl ood c oagul at i on • is b y: – En z y m e i n h i b i t o r s e g anti thr om bi n III - > ca sca d e i n h i b i t i o n – Fi b r i n o l y s i s b y p l a s m i n Th r o m b i n b o u n d t o t h r o m b o m o d u l i n Pr o t e i n C Ac t i v a t e d Pr o t e i n C In a c ti v a te s i n h i b i to r o f ti s s u e p l a s m i n o g e n Pl a s mi n o g e n Pl a s m i n Fi b r i n o l ysi s In a c ti v a te s V IIIa ,V a So … wh y d r u g s a f f e c t i n g h a e m o s t a s i s a n d t h r o m b o s i s ? Ve s s e l da m a g e Hyp e r c o a g - ul abi l i ty Bl o o d stasi s Vi r c h o w ’ s t r i a d TH R O M B O S I S So … w h y d r u g s a f f e c t i n g h a e m o s t a s i s a n d t h r o m b o s i s ? • So m e s i t u a t i o n s o f bl ood s tas i s le a d in g t o t h r o m b u s form ati on: – At r i a l f i b r i l l a t i o n - > c e r e b r a l e mb o l i s m o r - > r e n a l e mb o l i s m - > s a d d l e i l i a c t h r o mb u s i n c a t s – De e p v e i n t h r o m b o s i s ( DV T ) – Pu l m o n a r y e m b o l i s m www. s c i e n c e c a s e s . o r g ja a p a . c o m /. . . /s c r e e n /p u l m o n ar y 0 7 0 6 ar t . g i f So m e s i t u a t i o n s o f bl ood v es s el dam age le a d in g t o th r o m b u s fo r m a ti o n : • atheros c l eros i s – In c o r o n a r y v e s s e l s -- > my o c a r d i a l i n f a r c t i o n – In c a r o ti d a r te r i e s -- > st r oke www. u n i v i e . a c . a t / . . . / E K G / c o r o n a r y T h r o mb o s i s . j p g st a t i c . h o w st u f f w o r ks. c o m / g i f / a d a m / i m a g e s/ e n / a . . Rh e u ma t i c He a r t Di s e a s e ( RHD) On e c o n t e x t f o r a n t i c o a g u l a n t t h e r a p y - and pr ost het i c val ve r epl acem ent h t t p : / / t a k eh ea r t . t v / Dr ugs m ay ef f ec t : • co a g u la t io n ( f ib r in f o r ma t io n ) • pl atel ets – adhes i on and ac ti v ati on • fi bri nol y s i s Dr u g s a f f e c t i n g f i b r i n f o r m a t i o n • Pr o c o a g u l a n t d r u g s eg vit a min K • Inj ec tabl e anti c oagul ants eg hepari n, l ow - mo l e cu l a r - we i g h t h e p a r i n s – Us e d a c u t e l y f o r s h o r t t e r m a c t i o n • Or a l a n t i co a g u l a n t s eg wa r f a r i n – Us e d f o r p r o l o n g e d t h e r a p y In j e c ta b l e a n ti - co a g u l a n t s: Hepar i n • En h a n c e s a c t i v i t y o f anti thr om bi n III • AT I I I i s a n a t u r a l i n h i b i t o r t h a t in a c t iv a t e s X a a n d t h r o m b in • He p a r i n b i n d s A T I I I t o e x p o s e a c t i v e s i t e • LM W hepar i ns : – hav e s am e ef f ec t on f ac t or Xa, l es s ef f ec t on t hr om bi n – Ant i c oagul ant ef f ec t s ar e s i m i l ar In j e c ta b l e a n ti c o a g u l a n ts : Hepar i n • He p a r i n – Lar ge negat i v el y c har ged ( M W 60 - 100k D ) – No t o r a l l y a v a i l a b l e • Low m ol ec ul ar w ei ght hepar i n (M W 2 - 9k D ) – No t o r a l l y a v a i l a b l e – Longer el i m i nat i on hal f l i f e – Us e d f o r p a t i e n t s e l f a d mi n i s t r a t i o n @ h o me Coagul at i on c as c ade - si t e s o f a ct i o n s o f ant i c oagul ant s Ra n g D a l e Ri t t e r & M o o r e Ph a r m a c o l o g y 5 t h E dn fi g 2 0 . 6 He pa r i n LM W H ep a r i n Co a g u l a t i o n c a s c a d e - a di r ec t t hr ombi n i nhi bi t or Coagul at i on c as c ade - si t e s o f ac t i ons of ant i c oagul ant s Ra n g D a l e Ri t t e r & M o o r e Ph a r m a c o l o g y 5 t h E dn fi g 2 0 . 6 He pa r i n LM W H ep a r i n Hepar i n: adv er s e ef f ec t s • Wh e n h e p a r i n i s u s e d l o n g t e r m t h e e f f e c t s n e e d t o b e mo n i t o r e d • (A P P T tes t i s us ed – me a su r e o f i n t r i n si c p a t h w a y) • Ha e m o r r h a g e • Throm boc y topaeni a (pl atel et defi c i enc y ) • Ost e o p o r o si s ( me ch a n i sm u n kn o w n ) Or al ant i c oagul ant s : “sw e e t mo u l d y cl o ve r d i se a se ”Vi t a mi n K • Es s e n t i a l f o r f o r m a t i o n o f c l o t t i n g f a c t o r s I I , VI I , I X, a n d X • Thes e m ol ec ul es al l requi re gam m a c arbox y l ati on after syn t h e sis • Re d u c e d v i t a m i n K i s a c o f a c t o r i n c a r b o x y l a t i o n o f gl utam ate Wa r f a r i n a n d i t s d e r i v a t i v e s : ro d e n t i c i d e s a n d m e d i c i n e s • Co u m a r i n d e r i v a t i v e s eg wa r f a r i n , b r o d i f a c o u m , brom adi al one • Inhi bi t reduc ti on of v i tam i n K , thereby i nhi bi ti ng gam m a c arbox y l ati on of gl utam ate i n fac tors II, V II, IX and X Me c h a n i s m o f a c t i o n o f V i t a mi n K a n d W a r f a r i n Ra n g Da l e Ri t t e r & M o o r e Ph a r m a c o l o g y 5 t h Ed n fi g 2 0 .5 Fi b r i n f o r m a t i o n a n d Vi t a m i n K www. r o b h a r v e y . c o m / a n i m a g e / r a t - ki l l e r - bai t - buc . . www. c a r t o o n s t o c k . c o m … a ta l e o f m i s a d v e n tu r e ! Wi l l Ra t t y b e c a u g h t o u t ? Wa r f a r i n a n d ot her c oum ar i n der i v at i v es • On l y a ct i ve i n vi vo • De l a y e d o n s e t o f a c t i o n • Do e s n ’ t affec t al ready ac ti v e fac tors Wa r f a r i n a n d C o u m a r i n d e r i v a t i v e s - Ad v e r s e Ef f e c t s • Ha e m o r r h a g e – Bl e e d i n g f r o m m u c o s a l s u r f a c e s a n d i n t o b o d y ca vi t i e s • Re v e r s a l – vi t a m i n K ( o r a l ) – phy t om enadi one nat ur al v i t am i n K ( i. v . ) – fr e s h fr o z e n p l a s m a Co u m a r i n De r i v a t i v e s a n d Ro d e n t i c i d e P o i s o n i n g • Fi r s t g e n e r a t i o n r o d e n t i c i d e s – mu l t i p l e f e e d p o i s o n s - lo w e r e f f ic a c y a n d s h o r t e r hal f l i fe • Se c o n d g e n e r a t i o n ro d e n t i c i d e s - si n g l e f e e d poi s ons - hi gher effi c ac y and lo n g e r h a lf lif e Br odi f ac oum Wa r f a r i n Look i ng f or ev i denc e of w ar f ar i n poi s oni ng ( or ef f i c ac y of w ar f ar i n t r eat m ent i n hum ans ) • Pr o t h r o m b i n T i m e ( PT ) – ti m e for c l ot for m ati on of pl as m a after addi ti on of C a 2+ and ti s s ue fac tor – A m e a s u r e o f t h e ext r in sic p at h w ay • Wh e n w a r f a r i n i s u s e d i n h u m a n m e d i c i n e a s a n anti c oagul ant, dr ug l ev el s ar e v er y l abi l e - re g u l a r m o n i t o ri n g is r e q u ir e d • Lets thi nk about w hat m i ght affec t w ar far i n l ev el s ..? Wa r f a r i n – Ph a r ma c o k i n e t i c s * • oral l y ac ti v e and rapi dl y abs orbed • st r o n g ly b o u n d t o p la sma p r o t e in ( 9 9 % ) Lev el s are affec ted by : • Di e t a r y Vi t a m i n K i n t a k e • Me t a b o l i c st a t e • Li v er heal th (s y nthes i s of c l otti ng fac tors ) • Dr u g i n t e r a c t i o n s *W a r f a r i n l e v e l s a n d a n t i co a g u l a n t e f f e ct s a r e v e r y l a b i l e New or al ant i c oagul ant agent s ( NO A C’ s ) • Ar e b e c o m i n g a v a i l a b l e • Or a l l y a v a i l a b l e • Mo r e p r e d i c t a b l e d o s e - re s p o n s e • Re d u c e d l a b o r a t o r y m o n i t o r i n g • Indi r ec t F ac tor Xa ( FX a ) i n h i b i t o rs • Di r e c t F a c t o r Xa in h ib it o r s • Di r e c t T h r o m b i n I n h i b i t o r s – re f Fr a n c h i n i & Ma n n u c c i (2 0 0 9 ) Eu r o p e a n J o u r n a l o f I n t e r n a l M e d i c i n e 2 0 : 5 6 2 - 568 New or al ant i c oagul ant agent s ( NO A C’ s ) re f Fr a n c h i n i & Ma n n u c c i (2 0 0 9 ) Eu r o p e a n J o u r n a l o f I n t e r n a l M e d i c i n e 2 0 : 5 6 2 - 568 Us e d o f f l a b e l f o r di s eas es of c oagul at i on i n dogs . eg IM H A Da g i b a t r a n appr ov ed f or us e in s t r o k e pr ev ent i on as s oc i at ed w i t h at r i al f i br i l l at i on Dr ugs af f ec t i ng pl at el et ac t i v at i on and adhes i on • ADP rec eptor antagoni s ts ( eg cl o p i d o g r e l ) • Throm box ane syn t h e sis in h ib it o r s (c y c l o - ox y genas e in h ib it o r s eg as pi r i n) Me c h a n i s m o f a c t i o n o f a n t i p l a t e l e t d r u g s As p i r i n s t o p s p l a t e l e t a c t i v a t i o n b y i n h i b i t i n g t h e e n z y m e c y c l o - ox y genas e 1. T hi s pr ev ent s t he s y nt hes i s of th r o m b o x a n e A 2 w h i c h n o r m a l l y c a u s e s p l a te l e t a g g r e g a ti o n . Cl o p i d o g r e l i n h i b i t s t h e a c t i v a t i o n o f t h e g l y c o p r o t e i n I I b / I I I a c o m p l e x b y p r e v e n t i n g a d e n o s i n e d i p h o s p h a t e bi ndi ng t o a pl at el et r ec ept or . T hi s i nhi bi t s pl at el et aggr egat i on. A nt agoni s t s of t he gl y c opr ot ei n I I b/ I I I a r ec ept or st o p p l a t e l e t a g g r e g a t i o n b y b l o cki n g t h e b i n d i n g o f f i b r i n o g e n t o t h e r e ce p t o r . Di p y r i d a m o l e i n c r e a s e s t h e p r o d u c t i o n o f p r o s t a c y c l i n , a p o t e n t i n h i b i t o r o f p l a t e l e t a g g r e g a t i o n . Ad a p t e d w i t h p e r m i s s i o n , f r o m t h e o r i g i n a l d i a g r a m , c o p y r i g h t o f t h e N a t i o n a l H e a r t F o u n d a t i o n o f Au s t r a l i a . No f u r t h e r r e p r o d u c t i o n o r m o d i f i c a t i o n i s a l l o we d . Mc C a n n A A u s t P r e s c r i b e r ( 3 0 ) p a g e 9 3 2 0 0 7 NS A I D’ s : Th r o m o b o x a n e (T X A 2 ) s y n t h e s i s in h ib it o r s • Throm box ane potent ac ti v ator of pl atel ets • Sy n t h e s i z e d i n p l a t e l e t s f r o m a r a c h i d o n i c a c i d ( m e m b r a n e fatty ac i d) • Re a c t i o n c a t a l y z e d b y c y c l o - ox y genas e As p i r i n - an i r r ev er s i bl e c y c l o - ox y genas e in h ib it o r Ø Re d u c e d t h r o m b o x a n e s y n t h e s i s Ø De c r e a s e d p l a t e l e t a g g r e g a t i o n Ø De c r e a s e d v a s o c o n s t r i c t i o n Pl at el et s hav e no nuc l eus ! Low dos e as pi r i n t her apy • Pl a t e l e t s a r e e x p o s e d t o a s p i r i n a s t h e y c i r c u l a t e i n t h e p o r t a l ve i n • As p i r i n c a u s e s i r r e v e r s i b l e i n h i b i t i o n o f C O X ( h e n c e thr om box ane s y nthes i s ) i n ex pos ed pl atel ets -- >D e c r e a s e d p l a t e l e t a g g r e g a t i o n • 90% of as pi r i n c l ear ed by fi r s t pas s m etabol i s m i n l i v er SO … • En d o t h e l i a l p r o d u c t i o n o f p r o s t a g l a n d i n I 2 (P G I 2 ) i s p re s e rv e d • à benef i c i al va so d i l a t i o n i s p r e se r ve d (A g re a t p h a rm a c o k in e t ic s t o ry ! ) Ot h e r a n t i p l a t e l e t d r u g s • ADP r e c e p t o r a n t a g o n i s t s ( eg clo p id ig r e l ) – Pr e v e n t b i n d i n g o f AD P t o i t s r e c e p t o r o n p l a t e l e t s – Th e r e b y p r e v e n t p l a t e l e t a c t i v a t i o n – Gi v e n o r a l l y a s p r o d r u g Cont r ol of bl ood c oagul at i on: F i br i nol y s i s • is b y: – En z y m e i n h i b i t o r s e g anti thr om bi n III – fi br i nol y s i s Th r o m b i n b o u n d t o th r o m b o m o d u l i n Pr o t e i n C Ac t i v a t e d Pr o t e i n C In a c ti v a te s i n h i b i to r o f ti s s u e p l a s m i n o g e n Pl a s mi n o g e n Pl a s m i n Fi b r i n o l ysi s In a c ti v a te s V IIIa ,V a ST R EPT O KI N ASE AL T EPL ASE Fi b r i n o l y t i c d r u g s • St r e p t o k i n a s e : – Ac t i v a t e s p l a s m i n o g e n – Us e d i n t r a v e n o u s l y – An t i g e n i c s o s i n g l e u s e – Ca n b e u s e d i n s i t u a t i o n s wh e r e a n i m a l s p r e s e n t wi t h thr om boti c di s eas e ( eg thr om boem bol i c oc c l us i on of the ilia c a r t e r ie s in c a t s ) In s u m m a r y … o r w h a t ’ s i mpor t ant • Th e m e c h a n i s m o f haem os tas i s– Vas oc ons t r i c t i on – Pl at el et ac t i v at i on – Co a g u l a t i o n ( f i b r i n f o r ma t i o n ) • Dr u g s a n d t o x i c a g e n t s t h a t a f f e c t c o a g u l a t i o n – Or al ant i c oagul ant s / r odent i c i des ( eg wa r f a r i n ) – In j e c ta b l e a n ti c o a g u l a n ts ( eg hepar i n) – Ne w a n t i - co a g u l a n t d r u g s • An t i p l a t e l e t d r u g s – CO X i n h i b i t o r s ( eg asp i r i n ) – AD P r ec ept or ant agoni s t s ( eg cl o p i d i g r e l ) • Fi b r i n o l y t i c d r u g s – St r ept ok i nas e, Fu r t h e r r e a d i n g • “ Th e f i f t y y e a r q u e s t t o r e p l a c e w a r f a r i n ” Po s t e r i n Na t u r e Re v i e ws Dr u g Di s c o v e r y 2011 Jef f r ey W ei t z ht t p: / / www. n a t u r e . c o m /r e v i e w s /m u l ti m e d i a /a n ti c o a g u l a n ts / in d e x . h t m l A g r e a t a n i m a t i o n","libVersion":"0.2.2","langs":""}